309 related articles for article (PubMed ID: 34484468)
41. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
42. Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival.
Pocha K; Mock A; Rapp C; Dettling S; Warta R; Geisenberger C; Jungk C; Martins LR; Grabe N; Reuss D; Debus J; von Deimling A; Abdollahi A; Unterberg A; Herold-Mende CC
Clin Cancer Res; 2020 May; 26(9):2231-2243. PubMed ID: 31953311
[TBL] [Abstract][Full Text] [Related]
43. Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Takashima Y; Sakakibara-Konishi J; Hatanaka Y; Hatanaka KC; Ohhara Y; Oizumi S; Hida Y; Kaga K; Kinoshita I; Dosaka-Akita H; Matsuno Y; Nishimura M
Clin Lung Cancer; 2018 Jul; 19(4):352-359.e1. PubMed ID: 29544718
[TBL] [Abstract][Full Text] [Related]
44. Low PD-1 Expression in Cytotoxic CD8
Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
[No Abstract] [Full Text] [Related]
45. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
46. Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma.
Koh YW; Park B; Jung SH; Han JH; Haam S; Lee HW
Front Immunol; 2023; 14():1137880. PubMed ID: 37033978
[TBL] [Abstract][Full Text] [Related]
47. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
Yu H; Brustugun OT; Ekman S; Botling J; La Fleur L; Micke P; Solberg S; Berglund A; Rivard C; Hirsch FR
Clin Lung Cancer; 2021 Jul; 22(4):e555-e562. PubMed ID: 33214079
[TBL] [Abstract][Full Text] [Related]
48. Associations of
Chang JH; Lai TC; Yang PJ; Shih PC; Yang YC; Lee KL; Liu TC; Tsao TC; Yang SF; Chien MH
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126605
[TBL] [Abstract][Full Text] [Related]
49. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
[TBL] [Abstract][Full Text] [Related]
50. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
[TBL] [Abstract][Full Text] [Related]
51. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
[TBL] [Abstract][Full Text] [Related]
52. EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.
Chen Z; Chen J; Ren D; Zhang J; Yang Y; Zhang H; Mao B; Ma H
Aging (Albany NY); 2020 Dec; 13(1):598-618. PubMed ID: 33288738
[TBL] [Abstract][Full Text] [Related]
53. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
54. Identification immunophenotyping of lung adenocarcinomas based on the tumor microenvironment.
Tan Q; Huang Y; Deng K; Lu M; Wang L; Rong Z; Zhao W; Li S; Xu Z; Fan L; Li K; Li Z
J Cell Biochem; 2020 Nov; 121(11):4569-4579. PubMed ID: 32030808
[TBL] [Abstract][Full Text] [Related]
55. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
Shen M; Jiang K; Sui Y; Xu Z; Cui H; Wang Y; Zhang H; Xu Z; Xu W; Ding Q; Chen Y
Lung Cancer; 2021 Oct; 160():84-91. PubMed ID: 34479175
[TBL] [Abstract][Full Text] [Related]
56. Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
Fukuda H; Arai K; Mizuno H; Nishito Y; Motoi N; Arai Y; Hiraoka N; Shibata T; Sonobe Y; Kayukawa Y; Hashimoto E; Takahashi M; Fujii E; Maruyama T; Kuwabara K; Nishizawa T; Mizoguchi Y; Yoshida Y; Watanabe SI; Yamashita M; Kitano S; Sakamoto H; Nagata Y; Mitsumori R; Ozaki K; Niida S; Kanai Y; Hirayama A; Soga T; Tsukada K; Yabuki N; Shimada M; Kitazawa T; Natori O; Sawada N; Kato A; Yoshida T; Yasuda K; Ochiai A; Tsunoda H; Aoki K
Cancer Sci; 2024 Jun; 115(6):1763-1777. PubMed ID: 38527308
[TBL] [Abstract][Full Text] [Related]
57. Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.
Tian Y; Zhai X; Yan W; Zhu H; Yu J
Cancer Med; 2021 Jan; 10(1):3-14. PubMed ID: 33230935
[TBL] [Abstract][Full Text] [Related]
58. SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma.
Yuan L; Wu X; Zhang L; Yang M; Wang X; Huang W; Pan H; Wu Y; Huang J; Liang W; Li J; Zhu X; Wang S; Guan J; Liu L
Cancer Immunol Immunother; 2022 Feb; 71(2):399-415. PubMed ID: 34181042
[TBL] [Abstract][Full Text] [Related]
59. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
60. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
